153 related articles for article (PubMed ID: 23982605)
1. Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma.
Meniawy TM; Creaney J; Lake RA; Nowak AK
Br J Cancer; 2013 Oct; 109(7):1813-20. PubMed ID: 23982605
[TBL] [Abstract][Full Text] [Related]
2. Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.
Billé A; Krug LM; Woo KM; Rusch VW; Zauderer MG
J Thorac Oncol; 2016 Feb; 11(2):249-55. PubMed ID: 26845118
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.
Linton A; Pavlakis N; O'Connell R; Soeberg M; Kao S; Clarke S; Vardy J; van Zandwijk N
Br J Cancer; 2014 Oct; 111(9):1860-9. PubMed ID: 25188323
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.
Otoshi T; Kataoka Y; Kaku S; Iki R; Hirabayashi M
In Vivo; 2018; 32(2):445-450. PubMed ID: 29475935
[TBL] [Abstract][Full Text] [Related]
5. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
[TBL] [Abstract][Full Text] [Related]
6. Relationship between prognosis and neutrophil: lymphocyte and platelet:lymphocyte ratios in patients with malignant pleural mesotheliomas.
Cihan YB; Ozturk A; Mutlu H
Asian Pac J Cancer Prev; 2014; 15(5):2061-7. PubMed ID: 24716935
[TBL] [Abstract][Full Text] [Related]
7. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
[TBL] [Abstract][Full Text] [Related]
8. The Value of COX-2, NF-κB, and Blood Routine Indexes in the Prognosis of Malignant Peritoneal Mesothelioma.
Yin W; Zheng G; Su S; Liang Y
Oncol Res Treat; 2019; 42(6):334-341. PubMed ID: 31063993
[TBL] [Abstract][Full Text] [Related]
9. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.
Kao SC; Klebe S; Henderson DW; Reid G; Chatfield M; Armstrong NJ; Yan TD; Vardy J; Clarke S; van Zandwijk N; McCaughan B
J Thorac Oncol; 2011 Nov; 6(11):1923-9. PubMed ID: 22011651
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.
Yamagishi T; Fujimoto N; Nishi H; Miyamoto Y; Hara N; Asano M; Fuchimoto Y; Wada S; Kitamura K; Ozaki S; Kishimoto T
Lung Cancer; 2015 Oct; 90(1):111-7. PubMed ID: 26259877
[TBL] [Abstract][Full Text] [Related]
11. Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.
Suzuki H; Asami K; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Okishio K; Kawaguchi T; Atagi S; Kawase I
Lung; 2014 Feb; 192(1):191-5. PubMed ID: 24141556
[TBL] [Abstract][Full Text] [Related]
12. Relation between neutrophil/lymphocyte ratio and primary tumor metabolic activity in patients with malign pleural mesothelioma.
Özyürek BA; Özmen Ö; Özdemirel TŞ; Erdoğan Y; Kaplan B; Kaplan T
Clin Respir J; 2018 Feb; 12(2):646-651. PubMed ID: 27768834
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
14. Inflammation-based prognostic indices in malignant pleural mesothelioma.
Pinato DJ; Mauri FA; Ramakrishnan R; Wahab L; Lloyd T; Sharma R
J Thorac Oncol; 2012 Mar; 7(3):587-94. PubMed ID: 22307011
[TBL] [Abstract][Full Text] [Related]
15. The Neutrophil to Lymphocyte Ratio May Predict Benefit from Chemotherapy in Lung Cancer.
Liu D; Jin J; Zhang L; Li L; Song J; Li W
Cell Physiol Biochem; 2018; 46(4):1595-1605. PubMed ID: 29694985
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems.
Edwards JG; Abrams KR; Leverment JN; Spyt TJ; Waller DA; O'Byrne KJ
Thorax; 2000 Sep; 55(9):731-5. PubMed ID: 10950889
[TBL] [Abstract][Full Text] [Related]
17. Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.
Ghanim B; Klikovits T; Hoda MA; Lang G; Szirtes I; Setinek U; Rozsas A; Renyi-Vamos F; Laszlo V; Grusch M; Filipits M; Scheed A; Jakopovic M; Samarzija M; Brcic L; Stancic-Rokotov D; Kern I; Rozman A; Dekan G; Klepetko W; Berger W; Glasz T; Dome B; Hegedus B
Br J Cancer; 2015 Mar; 112(5):783-92. PubMed ID: 25633038
[TBL] [Abstract][Full Text] [Related]
18. The value of inflammatory parameters in the prognosis of malignant mesothelioma.
Abakay O; Tanrikulu AC; Palanci Y; Abakay A
J Int Med Res; 2014 Apr; 42(2):554-65. PubMed ID: 24573972
[TBL] [Abstract][Full Text] [Related]
19. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
20. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Gutierrez-Sainz L; Cruz P; Martinez-Recio S; Higuera O; Esteban-Rodriguez MI; Arias-Lotto F; Gonzalez RA; De Castro-Carpeño J
Clin Transl Oncol; 2021 Oct; 23(10):2030-2035. PubMed ID: 33837910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]